Juno Therapeutics Reaches Analyst Target Price
January 18, 2018 at 09:19 AM EST
In recent trading, shares of Juno Therapeutics Inc (JUNO) have crossed above the average analyst 12-month target price of $57.18, changing hands for $69.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..